重點：Two-thirds of participants were randomly picked to receive the mRNA-based vaccine made by Pfizer, based in New York City, and BioNTech, in Mainz, Germany, at least eight weeks after their first dose. A control group of 232 people has not yet received a booster. The study was led by the Carlos III Health Institute in Madrid. 他的對照組是「只打一針的人」。
啊幹拎良勒，混打看起來沒問題就看臨床實測結果講話啊？啊有時候要看臨床有時候又不看是怎樣啦？你他媽的乾脆說看提意見的人是誰來決定好了……
他的對照組是「只打一針的人」。